Back
About
Eikon Therapeutics is a clinical-stage pharmaceutical company focused on developing novel therapies to treat multiple types of cancer. The company is currently conducting clinical trials across several drug candidates in its pipeline, including:
-
EIK1001 for the treatment of advanced melanoma, evaluated in Phase 2/3 clinical trials involving approximately 740 patients across 22 countries;
-
EIK1001 for the treatment of Stage IV non-small cell lung cancer (NSCLC), studied in Phase 2 clinical trials involving approximately 750 patients, along with additional U.S.-based trials enrolling approximately 60 patients;
-
EIK1003 and EIK1004, selective PARP1 inhibitors, being evaluated in Phase 1/2 clinical trials involving approximately 65 patients with ovarian cancer and 16 patients with breast cancer; and
-
EIK1005, a WRN helicase inhibitor designed to target tumors, with a Phase 1/2 clinical trial expected to begin dosing in early 2026.
Headquarters
230 Harriet Tubman Way Millbrae, California 94030
Financial information
Underwriters
J.P.Morgan, Morgan Stanley, BofA Securities, Cantor
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.